This Biotech Stock Is Flying On Its Allergan-Rivaling Migraine Drug [Investor's Business Daily]
Biohaven Ltd. Common Shares (BHVN)
Last biohaven ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Investors Business Daily
Related news Biohaven Pharmaceutical ( BHVN ) soared Monday after its acute migraine treatment showed promise in a Phase 3 study — helping Biohaven stock approach a breakout. In afternoon trading on the stock market today , Biohaven stock rocketed 17.7%, near 40. Shares began consolidating this summer with a buy point at 44.38. A single dose of its orally dissolving tablet, rimegepant, provided rapid pain relief, separating from the placebo as early as 15 minutes, Biohaven said in a news release. The results reached statistically significant levels at the one-hour mark. Biohaven expects to ask the Food and Drug Administration to approve two versions of rimegepant in the first half of 2019. Researchers are testing rimegepant as a regular tablet and as a tablet that dissolves more rapidly. "We expect approval in the first half of 2020," Needham analyst Alan Carr said in a note to clients. "Results announced today will help differentiate rimegepant from ubrogepant ( Allergan ( AGN )) du
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at UBS Group AG from $59.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesPR Newswire
- Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Biohaven Announces Pricing of $230 Million Public Offering of Common Shares [Yahoo! Finance]Yahoo! Finance
BHVN
Earnings
- 11/14/23 - Miss
BHVN
Sec Filings
- 4/25/24 - Form 4
- 4/23/24 - Form 4
- 4/23/24 - Form 4
- BHVN's page on the SEC website